$798 Million is the total value of Rhenman & Partners Asset Management AB's 93 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 14.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Buy | Vertex Pharmaceuticals Inc | $31,512,000 | -7.2% | 186,000 | +0.4% | 3.95% | +5.6% |
| HZNP | New | Horizon Therapeutics Plc | $27,911,000 | – | 1,025,000 | +100.0% | 3.50% | – |
| NVCR | Sell | NovoCure Ltd Reg | $25,425,000 | +9.9% | 340,000 | -7.1% | 3.19% | +25.1% |
| ALXN | Buy | Alexion Pharmaceuticals Inc | $24,221,000 | -8.9% | 247,303 | +21.8% | 3.04% | +3.7% |
| ESPR | Buy | Esperion Therapeutics Inc | $24,044,000 | +25.4% | 655,854 | +59.2% | 3.01% | +42.7% |
| NKTR | Buy | Nektar Therapeutics | $21,858,000 | -15.3% | 1,200,000 | +65.5% | 2.74% | -3.6% |
| ABMD | Buy | Abiomed Inc | $21,347,000 | -11.8% | 120,000 | +29.2% | 2.68% | +0.4% |
| BMY | Buy | Bristol Myers Squibb Co | $21,045,000 | +37.1% | 415,000 | +22.6% | 2.64% | +56.1% |
| MDT | Buy | Medtronic Plc Reg | $20,118,000 | +26.8% | 185,218 | +13.7% | 2.52% | +44.4% |
| BMRN | Buy | BioMarin Pharmaceutical Inc | $19,579,000 | -18.8% | 290,491 | +3.2% | 2.45% | -7.5% |
| JAZZ | Sell | Jazz Pharmaceuticals Plc | $19,221,000 | -28.0% | 150,000 | -19.9% | 2.41% | -18.0% |
| CVS | Sell | CVS Health Corp | $19,159,000 | +2.3% | 303,768 | -11.6% | 2.40% | +16.4% |
| ABT | Sell | Abbott Laboratories | $18,417,000 | -15.6% | 220,114 | -15.2% | 2.31% | -4.0% |
| MRK | New | Merck & Co Inc | $18,099,000 | – | 215,000 | +100.0% | 2.27% | – |
| LLY | Sell | Eli Lilly & Co | $16,775,000 | -5.4% | 150,000 | -6.2% | 2.10% | +7.7% |
| UNH | Sell | United Health Group Inc | $16,734,000 | -34.7% | 77,000 | -26.7% | 2.10% | -25.7% |
| BDX | Sell | Becton Dickinson & Co | $15,936,000 | -21.0% | 63,000 | -21.2% | 2.00% | -10.0% |
| HUM | Sell | Humana Inc | $15,340,000 | -44.9% | 60,000 | -42.9% | 1.92% | -37.3% |
| BSX | Sell | Boston Scientific Corp | $15,055,000 | -9.7% | 370,000 | -4.6% | 1.89% | +2.8% |
| ANTM | Sell | Anthem Inc | $14,406,000 | -43.3% | 60,000 | -33.3% | 1.81% | -35.5% |
| GKOS | Sell | Glaukos Corp | $14,352,000 | -19.3% | 229,600 | -2.7% | 1.80% | -8.2% |
| NBIX | Sell | Neurocrine Biosciences Inc | $13,480,000 | -11.3% | 149,600 | -16.9% | 1.69% | +1.0% |
| ABBV | New | AbbVie Inc | $12,872,000 | – | 170,000 | +100.0% | 1.61% | – |
| SGEN | Buy | Seattle Genetics Inc Reg | $12,699,000 | +35.5% | 148,700 | +9.8% | 1.59% | +54.3% |
| REGN | Buy | Regeneron Pharmaceuticals Inc | $12,492,000 | -11.3% | 45,031 | +0.0% | 1.57% | +0.9% |
| GTHX | Buy | G1 Therapeutics Inc Reg | $12,202,000 | +45.1% | 535,657 | +95.3% | 1.53% | +65.2% |
| CI | Sell | Cigna Corp Reg | $12,143,000 | -19.9% | 80,000 | -16.8% | 1.52% | -8.8% |
| IMMU | Sell | Immunomedics Inc | $11,271,000 | -4.5% | 850,000 | -0.2% | 1.41% | +8.6% |
| TMO | Buy | Thermo Fisher Scientific Inc | $11,068,000 | +26.5% | 38,000 | +27.5% | 1.39% | +43.9% |
| FGEN | Sell | FibroGen Inc | $10,909,000 | -30.5% | 295,000 | -15.1% | 1.37% | -20.9% |
| MYOK | Sell | MyoKardia Inc Reg | $10,430,000 | -7.6% | 200,000 | -11.1% | 1.31% | +5.2% |
| MGNX | Sell | Macrogenics Inc | $10,200,000 | -29.9% | 799,373 | -6.7% | 1.28% | -20.2% |
| XNCR | Sell | Xencor Inc | $10,204,000 | -22.0% | 302,523 | -5.4% | 1.28% | -11.3% |
| EXAS | Buy | Exact Sciences Corp Reg | $9,741,000 | -8.3% | 107,786 | +19.8% | 1.22% | +4.4% |
| IOVA | Sell | Iovance Biotherapeutics Inc Reg | $9,464,000 | -48.6% | 520,000 | -30.7% | 1.19% | -41.5% |
| AERI | Buy | Aerie Pharmaceuticals Inc | $9,130,000 | +18.8% | 475,000 | +82.7% | 1.14% | +35.3% |
| HCA | Sell | HCA Healthcare Inc | $9,032,000 | -50.9% | 75,000 | -44.9% | 1.13% | -44.2% |
| LIVN | Sell | Livanova Plc | $8,855,000 | -18.0% | 120,000 | -20.0% | 1.11% | -6.6% |
| ABC | Sell | AmerisourceBergen Corp | $8,151,000 | -32.4% | 99,000 | -30.0% | 1.02% | -23.1% |
| EW | Buy | Edwards Lifesciences Corp | $8,045,000 | +37.9% | 36,585 | +15.8% | 1.01% | +56.9% |
| AGIO | Buy | Agios Pharmaceuticals Inc | $7,938,000 | -20.4% | 245,002 | +22.5% | 1.00% | -9.5% |
| MRTX | Sell | Mirati Therapeutics Inc Reg | $7,791,000 | -58.4% | 100,000 | -45.1% | 0.98% | -52.7% |
| MDCO | Sell | Medicines Co | $7,650,000 | +4.9% | 153,000 | -23.5% | 0.96% | +19.4% |
| CNC | Sell | Centene Corp | $7,571,000 | -51.1% | 175,000 | -40.7% | 0.95% | -44.3% |
| ARNA | Sell | Arena Pharmaceuticals Inc Reg | $7,094,000 | -28.8% | 155,000 | -8.8% | 0.89% | -19.0% |
| SGMO | Sell | Sangamo Therapeutics Inc Reg | $6,650,000 | -22.2% | 734,811 | -7.4% | 0.83% | -11.5% |
| OMCL | Sell | Omnicell Inc | $6,504,000 | -24.7% | 90,000 | -10.3% | 0.82% | -14.3% |
| ITCI | Sell | Intra-Cellular Therapies Inc | $6,350,000 | -48.5% | 850,000 | -10.5% | 0.80% | -41.4% |
| AMRN | Buy | Amarin Corp Plc spons ADR repr 1 Sharespons adr new | $6,064,000 | -10.8% | 400,000 | +14.0% | 0.76% | +1.5% |
| New | Incyte Corp Ltd | $5,938,000 | – | 80,000 | +100.0% | 0.74% | – | |
| CHRS | Sell | Coherus BioSciences Inc | $5,875,000 | -31.8% | 290,000 | -25.6% | 0.74% | -22.4% |
| RARX | Buy | Ra Pharmaceuticals Inc Reg | $5,771,000 | -16.2% | 244,000 | +6.6% | 0.72% | -4.6% |
| EXEL | Sell | Exelixis Inc | $5,659,000 | -42.4% | 320,000 | -30.4% | 0.71% | -34.5% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $5,549,000 | -6.2% | 69,000 | -15.4% | 0.70% | +6.7% |
| STML | Buy | Stemline Therapeutics Inc Reg | $5,320,000 | -29.7% | 511,023 | +3.4% | 0.67% | -20.0% |
| DPLO | Sell | Diplomat Pharmacy Inc Reg | $5,194,000 | -29.1% | 1,060,000 | -11.9% | 0.65% | -19.3% |
| BLUE | Sell | Bluebird Bio Inc | $4,775,000 | -46.4% | 52,000 | -25.7% | 0.60% | -38.9% |
| EPZM | Sell | Epizyme Inc Reg | $4,642,000 | -25.1% | 450,028 | -8.8% | 0.58% | -14.7% |
| DVAX | Dynavax Technologies Corp | $4,413,000 | -10.4% | 1,234,335 | 0.0% | 0.55% | +2.0% | |
| ALKS | Buy | Alkermes Plc | $4,292,000 | +58.1% | 220,000 | +82.7% | 0.54% | +79.9% |
| SILK | New | Silk Road Medical Inc Reg | $4,066,000 | – | 125,000 | +100.0% | 0.51% | – |
| RDUS | New | Radius Health Inc Reg | $3,863,000 | – | 150,000 | +100.0% | 0.48% | – |
| RIGL | Sell | Rigel Pharmaceuticals Inc | $3,740,000 | -36.7% | 2,000,000 | -11.7% | 0.47% | -28.0% |
| DERM | Buy | Dermira Inc Reg | $3,510,000 | -26.6% | 549,300 | +9.8% | 0.44% | -16.5% |
| HMSY | Sell | HMS Holdings Corp Reg | $3,388,000 | +4.6% | 98,300 | -1.7% | 0.42% | +19.0% |
| ICPT | Buy | Intercept Pharmaceuticals Inc | $3,159,000 | +5.6% | 47,600 | +26.6% | 0.40% | +20.0% |
| AIMT | Aimmune Therapeutics Inc Reg | $3,124,000 | +0.6% | 149,201 | 0.0% | 0.39% | +14.6% | |
| NSTG | Buy | NanoString Technologies Inc Reg | $3,069,000 | -15.7% | 142,126 | +18.4% | 0.38% | -4.0% |
| SAGE | Sell | Sage Therapeutics Inc | $2,806,000 | -29.2% | 20,000 | -7.6% | 0.35% | -19.3% |
| XLRN | Acceleron Pharma Inc Reg | $2,766,000 | -3.8% | 70,000 | 0.0% | 0.35% | +9.5% | |
| MDGL | Sell | Madrigal Pharmaceuticals Inc Reg | $2,587,000 | -33.7% | 30,000 | -19.4% | 0.32% | -24.7% |
| RVNC | Sell | Revance Therapeutics Inc | $2,261,000 | -9.8% | 173,917 | -10.0% | 0.28% | +2.5% |
| ABEO | Buy | Abeona Therapeutics Inc Reg | $2,260,000 | -27.2% | 1,000,000 | +54.1% | 0.28% | -17.3% |
| GH | New | Guardant Health Inc Reg | $2,234,000 | – | 35,000 | +100.0% | 0.28% | – |
| VRAY | Sell | ViewRay Inc Reg | $1,843,000 | -68.5% | 635,434 | -4.3% | 0.23% | -64.1% |
| ARQL | New | ArQule Inc Reg | $1,434,000 | – | 200,000 | +100.0% | 0.18% | – |
| VKTX | Sell | Viking Therapeutics Inc Reg | $1,376,000 | -43.1% | 200,000 | -31.4% | 0.17% | -35.3% |
| PIRS | Pieris Pharmaceuticals Inc Reg | $1,023,000 | -27.4% | 300,000 | 0.0% | 0.13% | -17.4% | |
| ACHN | Achillion Pharmaceuticals Inc | $1,000,000 | +34.2% | 277,800 | 0.0% | 0.12% | +52.4% | |
| ADVM | Adverum Biotechnologies Inc | $652,000 | -54.2% | 119,673 | 0.0% | 0.08% | -47.8% | |
| CVX | Chevron Corp | $353,000 | -4.6% | 2,974 | 0.0% | 0.04% | +7.3% | |
| BUD | Anheuser-Busch InBev SA ADR spons repr 1 Sharesponsored adr | $324,000 | +7.3% | 3,409 | 0.0% | 0.04% | +24.2% | |
| IBM | IBM Corp | $322,000 | +5.6% | 2,215 | 0.0% | 0.04% | +17.6% | |
| JPM | JPMorgan Chase & Co | $291,000 | +5.4% | 2,472 | 0.0% | 0.04% | +20.0% | |
| DIS | The Walt Disney Co | $271,000 | -6.9% | 2,083 | 0.0% | 0.03% | +6.2% | |
| SNSS | Sunesis Pharmaceuticals Inc Reg | $272,000 | -0.7% | 377,244 | 0.0% | 0.03% | +13.3% | |
| XOM | Exxon Mobil Corp | $272,000 | -7.8% | 3,854 | 0.0% | 0.03% | +6.2% | |
| WFC | Wells Fargo & Co | $266,000 | +6.8% | 5,272 | 0.0% | 0.03% | +22.2% | |
| F | Ford Motor Co | $267,000 | -10.4% | 29,164 | 0.0% | 0.03% | 0.0% | |
| QCOM | Qualcomm Inc | $259,000 | +0.4% | 3,391 | 0.0% | 0.03% | +14.3% | |
| JHG | Janus Henderson Group Plc Reg | $239,000 | +4.8% | 10,645 | 0.0% | 0.03% | +20.0% | |
| MSFT | Microsoft Corp | $213,000 | +3.9% | 1,532 | 0.0% | 0.03% | +17.4% | |
| SYMC | New | Symantec Corp | $207,000 | – | 8,761 | +100.0% | 0.03% | – |
| ONCE | Exit | Spark Therapeutics Inc | $0 | – | -10,000 | -100.0% | -0.11% | – |
| QGEN | Exit | Qiagen NV Reg | $0 | – | -60,000 | -100.0% | -0.27% | – |
| INCY | Exit | Incyte Corp Ltd | $0 | – | -100,000 | -100.0% | -0.94% | – |
| HBNC | Exit | Horizon Therapeutics Plc | $0 | – | -1,087,656 | -100.0% | -2.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-10-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.